News

This year, the British Society for Haematology held their annual scientific meeting online. Clinical experts presented some of the latest developments across all areas of lymphoma research.

A phase 1 trial of a new treatment called camidanlumab tesirine has found that this could be an effective option for people with lymphoma that has relapsed or is refractory after several previous courses of treatment.

Mogamulizumab has been approved for people with rare types of relapsed or refractory skin lymphoma, and acalabrutinib has been approved as a first-line treatment for some people with chronic lymphocytic leukaemia (CLL).

The results of the LOTIS-2 trial of loncastuximab tesirine for people with difficult-to-treat large B-cell lymphomas are encouraging.

Chlormethine gel is now available on the NHS in Scotland for adults with mycosis fungoides.

New guidelines give clear treatment recommendations for people with PTLD.

NICE has approved acalabrutinib for NHS use for some people with CLL.

NICE is not recommending mogamulizumab for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome.

A new CAR-T cell therapy has been approved on the NHS for people with relapsed or refractory mantle cell lymphoma.

Brentuximab vedotin is to be available on the NHS in Scotland for first-line treatment of systemic anaplastic large cell lymphoma.